What is CELU's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CELU?

P/E (TTM) is n/a and 52-week range is $0.56 to $2.55 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CELU figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CELU?

The company profile lists revenue (TTM) near $27M, net income (TTM) near $-9.33B, EPS (TTM) near $-3.59 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Celularity Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Florham Park, New Jersey, US, 28.9M shares outstanding, ISIN US1511902041 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Celularity Inc

$CELU

Health Care · Biotechnology

IR Run Scenarios

$1.56

+6.85%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. The company also provides contract manufacturing and development services to third parties.

Employees

123

Website

celularity.com/

IPO

2019-05-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)